Therefore, it is critical to investigate the mechanism of how the tumor immune microenvironment is shaped in the ER positive subtype (which encompasses the majority breast cancer cases) in order to increase the potential for utilization of immunotherapy for treatment. The gene discussed is ESR1; the disease is neoplasm.